Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK focuses on Neglected Diseases

by Rick Mullin
January 25, 2010 | A version of this story appeared in Volume 88, Issue 4

GlaxoSmithKline has launched a series of initiatives to promote research on neglected diseases. CEO Andrew Witty says GSK has made laboratory space available for 60 scientists at its Tres Cantos neglected disease research facility near Madrid. GSK will also offer 13,500 compounds that may inhibit the parasite Plasmodium falciparum, cause of the deadliest form of malaria in sub-Saharan Africa. And GSK has launched a research “knowledge pool” that will be managed by the nonprofit BIO Ventures for Global Health. The Emory Institute for Drug Discovery recently agreed to participate in the pool.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.